Acknowledgements The authors acknowledge the use of large language models, for improving the written English of the manuscript
The safest approach, according to current clinical guidance, is to restart semaglutide at its lowest available dose (0.25 mg weekly) and titrate up gradually following the standard schedule
Based on the populations studied in clinical trials to date, retatrutide has been investigated primarily in adults living with obesity defined as a body mass index (BMI) of 30 kg/m or above as well as in those who are overweight (BMI 27 kg/m or above) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidaemia
Their main use is as an add-on to metformin in patients who are insufficiently controlled on metformin alone, and an important indication is also in combination with insulin therapy.
While it's generally safe and there are no pharmacokinetic reactions between caffeine and creatine, there may be some problems with absorption